Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

President Trump with representatives of PhRMA. (Photo: Ron Sachs / Pool/Getty Images)

President Trump is scheduled to give a speech on drug prices next week, but few expect the policy proposals that will accompany it to pack a real punch to the pharmaceutical industry — unless the president goes off-script.

What they're saying: “We are hopeful the administration will embrace market-oriented policies that address patient affordability ... We would obviously be concerned if the administration pursued Medicare negotiation or importation which we think would take the system in the wrong direction," said Stephen Ubl, president and CEO of the Pharmaceutical Research and Manufacturers of America.

What to expect: The president's speech will coincide with a request for information on different drug price policies from the Department of Health and Human Services. But other actions are expected to follow.

  • The Centers for Medicare & Medicaid Services will be making enhancements to its drug pricing dashboard, which a person familiar with the proposal called "a shaming tool."
  • The Food and Drug Administration will continue its focus on getting more generics to market to enhance competition. Other actions are also expected from the different health care agencies.

Between the lines: The drug industry isn't worried about any of these. What gives them nightmares are things like giving Medicare the power to negotiate drug prices and allowing drugs to be imported from other countries — which Trump has talked about off the cuff but can be assumed to be completely off the table if his administration has its way.

  • "I would be deeply shocked if this administration came up with something for him that matched his ‘drug companies are getting away with murder rhetoric,'" said Rodney Whitlock, a lobbyist with the Campaign for Sustainable Drug Pricing.

So far, PhRMA has been pleased with the Trump administration. “I think in some ways, the administration is not getting the credit it deserves for the steps it’s taken to lower drug costs," Ubl said in an interview last week.

  • He pointed specifically to the FDA's work to clear the generic backlog, additional trade agreement enforcement and "discussions that they’ve been having around how to move the system towards more outcomes-based arrangements."
  • Responding to the upcoming speech, Ubl said the industry would welcome policies "like promoting value-driven health care and giving patients access to rebates at the pharmacy counter."

Yes, but: The president is known to literally throw his prepared remarks away when he's giving a speech he finds boring. Talking about getting generics to market faster and a new drug pricing dashboard are not the stuff of his typical campaign rally-style speeches.

  • “I think the entire health care stakeholder community should be nervous, because who knows where this could go?" Whitlock said.

Go deeper

DOJ pressed to enforce Al Jazeera foreign agent ruling

Illustration: Aïda Amer/Axios

The Justice Department is being pressed to enforce its own demand that the U.S. arm of Qatari broadcaster Al Jazeera register as a foreign agent.

Why it matters: The launch of Al Jazeera's new right-of-center U.S. media venture, Rightly, has refocused attention on the media company's alleged links to Doha, and DOJ's efforts to crack down on media outlets viewed as foreign interest mouthpieces.

Poll: Immigration is America's most-polarizing issue

Data: The American Aspirations Index/Populace; Chart: Will Chase/Axios

Immigration was found to be the most polarizing issue in America based on new polling from Populace.

Why it matters: Americans have surprisingly similar priorities for the U.S., but immigration stands out as one of the few issues with clear partisan differences. It underscores the challenge for advocates and lawmakers hoping to pass immigration reform in the coming weeks amid narrow margins in Congress.

2 hours ago - Politics & Policy

Lawmakers hide behind AG's investigation as Cuomo lingers

A billboard outside Albany, N.Y. Photo: Matthew Cavanaugh/Getty Images

New York Gov. Andrew Cuomo is politically wounded but not yet dead, several state lawmakers tell Axios.

The state of play: Most are holding their fire and punting to state Attorney General Letitia James' investigation into sexual harassment allegations. They expect the inquiry to be credible and thorough — and buy Cuomo badly needed breathing room.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!